Mylan cutting jobs at patch plant

Mylan headquarters
Mylan headquarters

Mylan ($MYL) expanded a plant in Vermont several years ago, bumping up the employment by 160 jobs as a result. But times have changed and the drugmaker says it will now make a 10% cut in an effort to streamline operations.

The company in an emailed statement said the 10% reduction works out to about 60 jobs to be eliminated at the Mylan Technologies plant in St. Albans, which makes transdermal patches. The generics maker said it is hopeful that most of the cuts can be achieved with a voluntary reduction program and that all of those leaving will get generous severance packages and those volunteering to leave will receive additional compensation. 

"The decision comes after a careful assessment of a number of factors impacting the site and is consistent with our ongoing efforts to operate our businesses as efficiently as possible," Nina Devlin, Mylan’s head of global communications, said in a statement. "MTI’s production of transdermal drug-delivery systems--patches that deliver medication through the skin--and related technologies will continue to be a critical part of Mylan’s global product portfolio and manufacturing network, and we remain committed to this site and the community.”

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

Mylan got into the transdermal patch business more than 20 years ago when it bought the facility in St. Albans from Bertek Labeling for $39 million. Transdermal patches are a specialty that not many companies do, although India’s Rusan Pharma last month opened a $15 million transdermal patch facility.

Mylan in 2013 completed an 85,000-square-foot, three-story expansion project at the plant that bumped up the total operating space at the Mylan Technologies facility to 391,000 square feet. Mylan at the time said it was adding 160 new jobs to the 590 already at the facility.

The announcement comes as the Canonsburg, PA-based generics maker is on another expansion binge, in which it will be taking on thousands of new employees. It has a $7.2 billion deal for Sweden’s Meda, which comes with about 4,500 employees. Two weeks ago, it said it would spend about $1 billion to get pick up topical skin meds from Renaissance Acquisition Holdings. In that deal it is getting two plants and a contract manufacturing business, as well as 1,200 employees in manufacturing and sales and administration.

- here’s the WCAX story

Related Articles:
Mylan expansions roll on 
Mylan gets topicals CDMO as part of $1B deal for skin products 
India's Rusan Pharma opens transdermal patch plant in Gujarat 
Mylan snags Meda, advances its OTC ambitions, with $7.2B deal

Read more on

Suggested Articles

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.

Pfizer is ponying up $500 million on top of $100 million already committed to a gene therapy manufacturing facility in North Carolina.